As Pharmacogenomics Matures, CRO-like Companies Try to Stake Out Own Ground | GenomeWeb

Taking advantage of a shift in pharmacogenomics strategies that has been evolving in recent years, a group of innovators has emerged to focus on genotyping patients before they are prescribed a treatment.

Fueling this group is the interest in theranostics, which has continued to build and accelerate as the Food and Drug Administration promised to issue draft guidelines for the products by the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.